IMPORTANCE Skin rejuvenation can be achieved effectively and safely by injection of a stabilized hyaluronic acid (HA)-based gel of nonanimal origin (NASHA) injection using a stamp-type electronic multineedle injector. OBJECTIVE To determine the efficacy and safety of NASHA using a stamp-type electronic multineedle injector, and if changes in skin physiology occur earlier than in previous trials. DESIGN, SETTING, AND PARTICIPANTS Twenty-five patients were recruited to this single-center, evaluator-blinded, prospective, balanced (1:1), split-face randomized clinical trial.One dermatologist who was blinded as to the treatment side evaluated the skin hydration, melanin content, erythema, and elasticity of both cheeks using a corneometer, a mexameter, and a reviscometer, respectively, at each follow-up visit (0, 1, 2, 4, 8, and 12 weeks postinjection). The subjects and two independent investigators assessed the clinical improvement using the Global Aesthetic Improvement Scale (GAIS) at the every visit. Twenty-four participants completed the study, and no participants withdrew due to adverse effects. INTERVENTIONS Each participant submitted to a single treatment with a NASHA injection to one side of the lower cheek. The cheek side to which the treatment was applied was chosen randomly.
Twenty-five patients were recruited to this single-center, evaluator-blinded, prospective, balanced (1:1), split-face randomized clinical trial. Twenty-four participants completed the study, and no participants withdrew due to adverse effects. Each participant submitted to a single treatment with a NASHA injection to one side of the lower cheek. One dermatologist who was blinded as to the treatment side evaluated the skin hydration, melanin content, erythema, and elasticity of both cheeks using a corneometer, a mexameter, and a reviscometer, respectively, at each follow-up visit (0, 1, 2, 4, 8, and 12 weeks postinjection). The subjects and two independent investigators assessed the clinical improvement using the Global Aesthetic Improvement Scale (GAIS) at the every visit. Adverse events were self-reported by the patients completing a questionnaire.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
25
stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Hydration Level
We measured a hydration level by a corneometer device (Courage \& Khazaka, Cologne, Germany). The range of hydration level was 0 (as dry as possible) \~120 AU (Arbitrary Unit)(most moist possible)
Time frame: 12 weeks
Elasticity
We measured a elasticity by a reviscometer device (Courage \& Khazaka, Cologne, Germany). The range of elasticity was 0 (most elastic possible as) \~400 AU(Arbitrary Unit) (inelastic as possible)
Time frame: 12 weeks
Melanin Index
We measured a melanin index by a mexameter device (Courage \& Khazaka, Cologne, Germany). The range of melanin index was 0 (as bright as possible) \~999 AU (Arbitrary Unit) (most dark possible).
Time frame: 12 weeks
Erythema Index
We measured an erythema index by a mexameter device (Courage \& Khazaka, Cologne, Germany). The range of erythema index is 0\~999 AU(Arbitrary Unit). The range of erythema index was 0 (as non-erythematous as possible) \~999 AU (most erythematous possible)
Time frame: 12 weeks
Global Aesthetic Improvement Scale (Investigator)
The therapeutic outcome was assessed by investigator using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse.
Time frame: 12 weeks
Global Aesthetic Improvement Scale (Subject)
The therapeutic outcome was assessed by patient self-assessment using the Global Aesthetic Improvement Scale (GAIS), which rates outcome on the following 5-point scale: 3, very much improved; 2, much improved; 1, improved; 0, no change; and -1, worse
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.